$2.110
+0.197 (+9.33%)Al cierre
- High
- 2.200
- Open
- 1.910
- VWAP
- 2.05
- Vol
- 3.31M
- Mkt Cap
- 27.78M
- Low
- 1.830
- Amount
- 6.78M
- EV/EBITDA, TTM
- -1.85
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
AI analysis of RenovoRx Inc (RNXT)
buyRenovoRx Inc is a good buy right now due to its recent strong performance and positive developments. The stock has increased by 99.95% year-to-date and recently reported a record revenue of $909,000 for Q2 2026, reflecting a 115% year-over-year growth. Additionally, the RSI is at 81.878, indicating strong momentum, while the analyst price target suggests significant upside potential from the current price of $1.67. The main risk is the company's ongoing net losses, with a net income of -2,911,000 USD reported for Q2 2026, which investors should monitor closely.
Métricas de valoración
Cronología de eventos
Noticias
8.509-02NewsfilterRenovoRx to Showcase Innovative Therapies at Investment Conference
2.008-26NASDAQ.COMRenovoRx Reports Phase 3 TIGeR-PaC Trial Data for RenovoCath
- 2.008-25Newsfilter
RenovoRx Publishes TIGeR-PaC Clinical Trial Data
8.508-21NASDAQ.COMRenovoRx Regains Nasdaq Compliance with Minimum Bid Price
- 8.508-21Newsfilter
RenovoRx Regains Nasdaq Compliance with Minimum Bid Price Requirement
RNXT FAQ — answered by Alphio AI
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
RenovoRx Inc is a good buy right now due to its recent strong performance and positive developments. The stock has increased by 99.95% year-to-date and recently reported a record revenue of $909,000 for Q2 2026, reflecting a 115% year-over-year growth. Additionally, the RSI is at 81.878, indicating strong momentum, while the analyst price target suggests significant upside potential from the current price of $1.67. The main risk is the company's ongoing net losses, with a net income of -2,911,000 USD reported for Q2 2026, which investors should monitor closely.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.